4 accused in Hyderabad rape-murder case killed in encounter: Police

Newsroom, Feb 7: Prime Minister Narendra Modi’s recent statement that there is no detention camp in India is no more a lie. That doesn’t mean that there are no detention camps in the country, but the name of the camps have changed. 

In December, at a mega rally at Ramlila Maidan, meant to launch the BJP's campaign for the assembly elections in Delhi, Mr Modi had stated: “The rumour of detention centres being spread by the Congress and urban Naxals is totally false. This is being done with a bad intention to destroy the country, it’s filled with evil motives; this is a lie, lie, lie.” He had further claimed: “Neither are any of the country’s Muslims being sent to detention centres nor is there any detention centre in India”

In reality there are at least six detention camps in jails in Assam to house foreigners found staying in India illegally. A month prior to PM’s statement, Union minister of the state for home affairs Nityanand Rai had revealed that the six camps in Assam housed 1,043 foreigners — 1,025 Bangladeshis and 18 Myanmarese. Apart from these, at least ten new detention centres are coming up.

Outside Assam too, the Maharashtra government, under the then chief minister Devendra Fadnavis, had identified land for the state’s first detention centre for illegal immigrants.

Besides, in a case relating to illegal immigrants in Karnataka High Court in November this year, the Centre had told the court that it had written to all state governments in 2014 and sent a follow-up letter in 2018 to have detention centres to house foreign nationals illegally staying in India.

Karnataka’s first detention centre, apparently meant to lodge illegal immigrants and migrants overstaying in the country, is already open in Sondekoppa village on the outskirts of Bengaluru. The facility with several rooms, a kitchen and toilets has been kept ready on the directions of the government. 

Meanwhile, Union Minister of state for home Nityanand Rai has told the Lok Sabha that the name "detention centre" has now been changed to "holding centre".

New Delhi, May 14: The National Investigation Agency (NIA) probing the Al-Hind Islamic State (IS) Bengaluru module case has announced a cash reward of Rs three lakh for wanted absconder Abdul Mateen Taahaa.

An NIA spokesperson in Delhi said, "We have declared a cash reward of Rs three lakh for providing any information leading to arrest of Taahaa." The spokesperson said that Taahaa, 26, a resident of Shimoga in Karnataka is wanted in Al-Hind ISIS Bengaluru module case that the agency registered this year. The NIA had taken over the probe from the Karnataka Police.

According to the NIA officials, the case relates to ISIS-linked terror group formed by arrested accused Mehboob Pasha, along with accused Khaja Moideen aka Jalal and his associates involved in the murder of a Hindu leader in Tamil Nadu. The official said that Pasha conducted several meetings in 2019 at his residence in Bengaluru to hatch the conspiracy, by radicalising and recruiting other co-accused to carry out terror activities and join ISIS in Afghanistan or Syria.

The NIA has arrested 12 accused namely Pasha, Imran aka Imran Khan, Mohammed Haneef Khan, Mohammed Mansoor Ali Khan, Saleem Khan aka Kolar Saleem, Hussain Sharieff, Ejaz Pasha aka Azaz Pasha, Zabiulla, Syed Azmathulla, Syed Fasiur Rehman, Mohammed Zaid and Sadiq Basha.

The official said that Taahaa is a friend of arrested accused Saleem and Zaid, through whom he contacted arrested accused Pasha of Al-Hind Trust and was also associated with his online foreign handler.

Tokyo, Mar 4: Takeda Pharmaceutical Co said on Wednesday it was developing a drug to treat COVID-19, the flu-like illness that has struck more than 90,000 people worldwide and killed over 3,000.

The Japanese drugmaker is working on a plasma-derived therapy to treat high-risk individuals infected with the new coronavirus and will share its plans with members of the U.S. Congress on Wednesday, it said in a statement.

Takeda is also studying whether its currently marketed and pipeline products may be effective treatments for infected patients.

"We will do all that we can to address the novel coronavirus threat...(and) are hopeful that we can expand the treatment options," Rajeev Venkayya, president of Takeda's vaccine business, said in the statement.

Takeda said it was in talks with various health and regulatory agencies and healthcare partners in the United States, Asia and Europe to move forward its research into the drug.

Its research requires access to the blood of people who have recovered from the respiratory disease or who have been vaccinated, once a vaccine is developed, Takeda said.